-
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
Campanella, A., Capasso, A., Heltai, S., Taccetti, C., Albi, E., Herishanu, Y., Haggenburg, S., Chatzikonstantinou, T., Doubek, M., Kättström, M., Giannopoulos, K., Simkovic, M., Moreno, C., Massaia, M., Bumbea, H., Alshemmari, S., Ranghetti, P., Perotta, E., Martini, F., Sant'Antonio, E., & 24 others , Apr 2024, In: American journal of hematology. 99, 4, p. 745-750 6 p.Research output: Contribution to journal › Letter › Academic › peer-review
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., & 23 others , 25 Jan 2024, In: New England journal of medicine. 390, 4, p. 301-313 13 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Groen, K., Stege, C. A. M., Nasserinejad, K., de Heer, K., van Kampen, R. J. W., Leys, R. B. L., Thielen, N., Westerman, M., Wu, K-L., Ludwig, I., Issa, D. E., Velders, G. A., Vekemans, M-C., Timmers, G-J., de Boer, F., Tick, L. W., Verbrugge, A., Buitenhuis, D., Cunha, S. M., van der Spek, E., & 9 others , 1 Sept 2023, In: EClinicalMedicine. 63, 102167.Research output: Contribution to journal › Article › Academic › peer-review
- All publications